Resultats de la cerca - Steven D. Nathan

Refinar resultats
  1. 1
    IPF clinical trial design and endpoints

    IPF clinical trial design and endpoints per Steven D. Nathan, Keith C. Meyer

    Publicat 2014
    Obtenir text complet
    Revisão
    Afegir a favorits
    Guardat en:
  2. 2
    Management of end-stage sarcoidosis: pulmonary hypertension and lung transplantation

    Management of end-stage sarcoidosis: pulmonary hypertension and lung transplantation per Oksana A. Shlobin, Steven D. Nathan

    Publicat 2012
    Obtenir text complet
    Revisão
    Afegir a favorits
    Guardat en:
  3. 3
    Derivation and validation of a simple multidimensional index incorporating exercise capacity parameters for survival prediction in idiopathic pulmonary fibrosis

    Derivation and validation of a simple multidimensional index incorporating exercise capacity parameters for survival prediction in idiopathic pulmonary fibrosis per Abhimanyu Chandel, Jean Pastré, S. Valéry, Christopher S. King, Steven D. Nathan

    Publicat 2022
    Obtenir text complet Obtenir text complet
    Artigo
    Afegir a favorits
    Guardat en:
  4. 4
    Pulmonary hypertension in advanced sarcoidosis: epidemiology and clinical characteristics

    Pulmonary hypertension in advanced sarcoidosis: epidemiology and clinical characteristics per Andrew F. Shorr, Donald L. Helman, D. B. Davies, Steven D. Nathan

    Publicat 2005
    Obtenir text complet
    Artigo
    Afegir a favorits
    Guardat en:
  5. 5
    Change in forced vital capacity and associated subsequent outcomes in patients with newly diagnosed idiopathic pulmonary fibrosis

    Change in forced vital capacity and associated subsequent outcomes in patients with newly diagnosed idiopathic pulmonary fibrosis per William M. Reichmann, Yanni Yu, Dendy Macaulay, Eric Q. Wu, Steven D. Nathan

    Publicat 2015
    Obtenir text complet Obtenir text complet
    Artigo
    Afegir a favorits
    Guardat en:
  6. 6
    Pulmonary hypertension in patients with pulmonary fibrosis awaiting lung transplant

    Pulmonary hypertension in patients with pulmonary fibrosis awaiting lung transplant per Andrew F. Shorr, Jennifer L. Wainright, Cindy Cors, Christopher J. Lettieri, Steven D. Nathan

    Publicat 2007
    Obtenir text complet Obtenir text complet
    Artigo
    Afegir a favorits
    Guardat en:
  7. 7
    The distance-saturation product predicts mortality in idiopathic pulmonary fibrosis

    The distance-saturation product predicts mortality in idiopathic pulmonary fibrosis per Christopher J. Lettieri, Steven D. Nathan, Robert Browning, Scott D. Barnett, Shahzad Ahmad, Andrew F. Shorr

    Publicat 2006
    Obtenir text complet Obtenir text complet
    Artigo
    Afegir a favorits
    Guardat en:
  8. 8
    SERIAL MEASURES OF PULMONARY ARTERY PRESSURES IN PATIENTS WITH IDIOPATHIC PULMONARY FIBROSIS

    SERIAL MEASURES OF PULMONARY ARTERY PRESSURES IN PATIENTS WITH IDIOPATHIC PULMONARY FIBROSIS per Steven D. Nathan, Shahzad Ahmad, James P. Koch, Scott D. Barnett, Niv Ad, Nelson A. Burton

    Publicat 2005
    Obtenir text complet Obtenir text complet
    Artigo
    Afegir a favorits
    Guardat en:
  9. 9
    Heart rate recovery after six‐minute walk test predicts pulmonary hypertension in patients with idiopathic pulmonary fibrosis

    Heart rate recovery after six‐minute walk test predicts pulmonary hypertension in patients with idiopathic pulmonary fibrosis per Jeffrey J. Swigris, Amy L. Olson, Oksana A. Shlobin, Shahzad Ahmad, Kevin K. Brown, Steven D. Nathan

    Publicat 2010
    Obtenir text complet
    Artigo
    Afegir a favorits
    Guardat en:
  10. 10
    The 6-min walk test as a primary end-point in interstitial lung disease

    The 6-min walk test as a primary end-point in interstitial lung disease per Sergio Harari, Athol U. Wells, Wim Wuyts, Steven D. Nathan, Klaus-Uwe Kirchgaessler, Monica Bengus, Jürgen Behr

    Publicat 2022
    Obtenir text complet Obtenir text complet
    Revisão
    Afegir a favorits
    Guardat en:
  11. 11
    Pulmonary artery size as a predictor of outcomes in idiopathic pulmonary fibrosis

    Pulmonary artery size as a predictor of outcomes in idiopathic pulmonary fibrosis per Stephanie Shin, Christopher S. King, Nitin Puri, Oksana A. Shlobin, Anne Brown, Shahzad Ahmad, Nargues Weir, Steven D. Nathan

    Publicat 2016
    Obtenir text complet Obtenir text complet
    Artigo
    Afegir a favorits
    Guardat en:
  12. 12
    Predicting Life Expectancy for Pirfenidone in Idiopathic Pulmonary Fibrosis

    Predicting Life Expectancy for Pirfenidone in Idiopathic Pulmonary Fibrosis per Mark Fisher, Steven D. Nathan, Christian Hill, J.D. Marshall, F. Dejonckheere, Per-Olof Thuresson, Toby M. Maher

    Publicat 2017
    Obtenir text complet Obtenir text complet
    Artigo
    Afegir a favorits
    Guardat en:
  13. 13
    Identifying Barriers to Idiopathic Pulmonary Fibrosis Treatment: A Survey of Patient and Physician Views

    Identifying Barriers to Idiopathic Pulmonary Fibrosis Treatment: A Survey of Patient and Physician Views per Toby M. Maher, Jeffrey J. Swigris, Michael Kreuter, Marlies Wijsenbeek, Nicola Cassidy, Lucy Ireland, Judit Axmann, Steven D. Nathan

    Publicat 2018
    Obtenir text complet
    Artigo
    Afegir a favorits
    Guardat en:
  14. 14
    Performance of the FORD Versus Other Available Models for the Noninvasive Prediction of Pulmonary Hypertension in Patients with Interstitial Lung Disease

    Performance of the FORD Versus Other Available Models for the Noninvasive Prediction of Pulmonary Hypertension in Patients with Interstitial Lung Disease per Ho Cheol Kim, Abhimanyu Chandel, Christopher S. King, Min Jee Kim, Malek Shawabkeh, Ambalavanan Arunachalam, Rade Tomic, Steven D. Nathan

    Publicat 2025
    Obtenir text complet
    Artigo
    Afegir a favorits
    Guardat en:
  15. 15
    Prevalence and impact of coronary artery disease in idiopathic pulmonary fibrosis

    Prevalence and impact of coronary artery disease in idiopathic pulmonary fibrosis per Steven D. Nathan, Ashwin Basavaraj, Cristina Reichner, Oksana A. Shlobin, Shahzad Ahmad, Joseph Kiernan, Nelson A. Burton, Scott D. Barnett

    Publicat 2010
    Obtenir text complet Obtenir text complet
    Artigo
    Afegir a favorits
    Guardat en:
  16. 16
    Lung Transplantation for Patients With COVID-19

    Lung Transplantation for Patients With COVID-19 per Christopher S. King, Hannah Mannem, Jasleen Kukreja, Shambhu Aryal, Daniel Tang, Jonathan P. Singer, Ankit Bharat, Jürgen Behr, Steven D. Nathan

    Publicat 2021
    Obtenir text complet
    Revisão
    Afegir a favorits
    Guardat en:
  17. 17
    The Antifibrotic Effects of Inhaled Treprostinil: An Emerging Option for ILD

    The Antifibrotic Effects of Inhaled Treprostinil: An Emerging Option for ILD per Martin Kolb, Stylianos E. Orfanos, Christopher Lambers, Kevin R. Flaherty, Alison Masters, Lisa Lancaster, Adam M. Silverstein, Steven D. Nathan

    Publicat 2022
    Obtenir text complet Obtenir text complet
    Revisão
    Afegir a favorits
    Guardat en:
  18. 18
    Derivation and validation of a noninvasive prediction tool to identify pulmonary hypertension in patients with IPF: Evolution of the model FORD

    Derivation and validation of a noninvasive prediction tool to identify pulmonary hypertension in patients with IPF: Evolution of the model FORD per Steven D. Nathan, Abhimanyu Chandel, Ya Wang, Jiawei Xu, Lixin Shao, Timothy R. Watkins, Jack Diviney, Christopher S. King, Ling Han

    Publicat 2023
    Obtenir text complet
    Artigo
    Afegir a favorits
    Guardat en:
  19. 19
    Pulmonary hypertension in the setting of interstitial lung disease: Approach to management and treatment. A consensus statement from the Pulmonary Vascular Research Institute's Innovative Drug Development Initiative—Group 3 Pulmonary Hypertension

    Pulmonary hypertension in the setting of interstitial lung disease: Approach to management and treatment. A consensus statement from the Pulmonary Vascular Research Institute's Inn... per Oksana A. Shlobin, Eric Shen, Stephen J. Wort, Lucilla Piccari, John Scandurra, Paul M. Hassoun, Sylvia Nikkho, Steven D. Nathan

    Publicat 2024
    Obtenir text complet Obtenir text complet
    Revisão
    Afegir a favorits
    Guardat en:
  20. 20
    Sustained Activation of Toll-Like Receptor 9 Induces an Invasive Phenotype in Lung Fibroblasts

    Sustained Activation of Toll-Like Receptor 9 Induces an Invasive Phenotype in Lung Fibroblasts per Varvara Kirillov, Jonathan T. Siler, Mahalakshmi Ramadass, Lingyin Ge, James E. Davis, Geraldine M. Grant, Steven D. Nathan, Gábor Járai, Glenda Trujillo

    Publicat 2015
    Obtenir text complet Obtenir text complet
    Artigo
    Afegir a favorits
    Guardat en:

Eines de cerca: